Chaput Nathalie, Schartz N E C, Andre Fabrice, Zitvogel Laurence
ERIT-M 02-08 INSERM, Department of Clinical Biology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France.
Adv Exp Med Biol. 2003;532:215-21. doi: 10.1007/978-1-4615-0081-0_17.
Exosomes are 60 to 90 nm membrane vesicles originating from late endosomes and secreted from most hematopoietic and epithelial cells in vitro. B cell derived-exosome antigenicity was first reported in 1996 in MHC class II restricted CD4+ T lymphocytes. In 1998, we reported that dendritic cell derived-exosomes are immunogenic in mice leading to tumor rejection. These findings have renewed the interest in exosomes. The current challenge consists in understanding the mechanisms and the physiological relevance of exosomes that could contribute to the design of the optimal exosome based-vaccination. Here, we will focus on the biological features pertaining to dendritic cell- and tumor cell derived-exosomes and will discuss their potential clinical implementation.
外泌体是源自晚期内体的60至90纳米膜囊泡，可在体外由大多数造血细胞和上皮细胞分泌。1996年首次报道了B细胞衍生外泌体的抗原性，其针对的是MHC II类限制性CD4 + T淋巴细胞。1998年，我们报道树突状细胞衍生的外泌体在小鼠中具有免疫原性，可导致肿瘤排斥。这些发现重新引发了对外泌体的兴趣。当前的挑战在于理解外泌体的机制及其生理相关性，这可能有助于设计基于外泌体的最佳疫苗。在此，我们将重点关注与树突状细胞和肿瘤细胞衍生外泌体相关的生物学特性，并讨论它们潜在的临床应用。
